

### Amendment of the Wakf Act

\*37. SHRI GHULAM RASOOL MATTO:

SHRI SYED SHAHABUDDIN:

Will the Minister of LAW, JUSTICE AND COMPANY AFFAIRS be pleased to state:

(a) whether Government propose to introduce a Bill in Parliament to replace or amend the Wakf Act;

(b) if so, by when it is likely to be introduced; and

(c) what are the major shortcomings or defects in the Wakf Act which are likely to be remedied through the new Bill?

THE MINISTER OF LAW, JUSTICE AND COMPANY AFFAIRS (SHRI JAGANNATH KAUSHAL): (a) to (c) Based on the recommendations of the Wakf Inquiry Committee, experience gained so far in the administration of the Wakf Act, 1954 and suggestions received from various sources, a draft Bill has been drawn up for making amendments to the Wakf Act, 1954. The draft Bill is under the active consideration of the Government and is being scrutinised in depth. The Bill is expected to be introduced in the Parliament as soon as possible. As final decisions on the proposed amendments are yet to be reached, it is not possible at this stage to indicate what they are.

#### Unauthorised production by multinational companies

\*38. SHRI K.V.R.S. BALA SUBBA RAO: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether it is a fact that M/s Abbott Labs, Glaxo, Fairdeal Corporation, Astra-IDL have unauthorisedly installed additional plant and machinery without the permission of Government and have attained unauthorised production;

1734 RS-3.

(b) what is their permitted capacity of formulations under different heads and what is their production during 1983, company-wise;

(c) whether these companies are manufacturing formulations without any approval; if so, what are the details thereof; and

(d) whether Government have taken any steps for physical verification of additional unauthorised plant, machinery and equipment, if so, what are the details of the units visited and the findings?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VASANTH SATHE): (a) and (d) The schemes of April, 1982 and April, 1983 provide for re-endorsement of capacity based on production performance.

However, I have already ordered of the spot verifications of the plant and machinery of M/s Glaxo, Astra-IDL, Abbott Labs, and Fairdeal Corporation with a view to examine whether these companies have unauthorisedly installed additional plant and machinery.

(b) The industrial approvals held by M/s Glaxo, Fairdeal Corporation and Astra-IDL do not specify the formulation capacities in all cases. The CO licence held by M/s Abbott Laboratories specifies the formulation capacities category-wise. Statement I gives the licensed capacity of M/s Abbott Laboratories as well as the production of formulation of these four companies to the extent information is available.

(c) A number of drug companies including these four companies, have claimed certain industrial approvals for the authority for production of different items but the validity of such claims has been found to be doubtful. A list of items of such drug formulations in respect of these four companies is given in Statement II.

## Statement I

S. No.	Name of the Company	Item	Unit	Production During		
				1979-80	1980-81	1981-82
1	2	3	4	5	6	7
1.	M/s Astra-IDL Ltd. (Source : REC 1982) Application	Tablets & Capsules	000 Nos.	26983	25034	27135
		Liquid Injectables	Litres Litres	411594 401	407425 680	483581 1160
2.	M/s Glaxo Laboratories (India) Ltd. (Source : REC, 1982) Application	Tablets & Capsules Liquid/Drops/Syrup Lotion/Solids/Powders Ointment	Million Nos. 000 Litres 000 Kgs 000 Kgs.	1984.43 3586.08 728.61 164.10	2325.42 2944.89 964.15 166.976	1958.19 3697.70 1278.91 197.73
3.	M/s Abbott Laboratories. (Source : REC, 1982) Application	Tablets* (Licenced Capacity—100 Million Tab.)	Million Nos.	112.711	122.008	141.158
		Liquids* (Licenced Capacity—2,36,000 Litres)	Lakh Litres	4.37	4.88	5.74
		Injectables* (Licenced capacity—18,79,000) Granules (Licenced Capacity—5737 Kgs.) Capsules* (Licenced Capacity—8 lakh Nos.)	Units : 9449 Litres Kgs. Nos.	2431769 12473.976	2632519 12396.505	2004605 20902.633
4.	M/s Fairdeal Corporation of India Ltd. (Source : REC, 1982) Application	Tablets & Capsules	Lakh Nos.	1189.53	1665.85	1703.84
		Liquids	Litres	517500	390500	417950
		Injectables	Litres	20094	16640	17455
		Granules	Kgs.	561150	834850	74750
		Cream Ointment	Kgs.	21490	20740	35770
		Powders	Kgs.	40000	31600	37400
		Ophthalmic	litres	37190	34480	44950
		E.N.T. Preparations.	Litres	14270	12380	14118

\*These have been further enhanced under April, 1982 Policy.

## Statement-

S.No.	Name of the Company	Name of Item
1	M/s Abbott Laboratories	1. Surbex Liquid 2. Pentothal Sodium Inj.
2	M/s Fairdeal Corporation (Pvt.) Ltd. Bombay	1. Pethidine Injection 2. Minaphillin Inj. 3. Vitcofol 4. Fairdical 5. Drosyn Group Ophthalmics 6. Varmycetin Ophthalmics 7. Spasmalka 8. Tonavit 9. Scabalcid 10. Fairgenol 11. Fenyl Benzoate Appln. 12. Fairgenol Obstetric 13. Cotaryl Group 14. Malzyme 15. Sylvenol 16. Tetracycline Cap. 17. Lipaton Cap. 18. Vitbin Complex Cap.
3	M/s Astra-IDL Ltd.	1. Linctus Codeine Co 2. Iteol 3. Mynatal 4. Vitoferrin 5. Vermitel 6. Water for Injection 7. Logacid 8. Mucosol 9. Morphine HCL 10. Morphine with Atropine 11. Pethidine

S. No. Name of the Company

Name of Item

12. Mynatal Tablets/Capsules

13. Logacid Tablets

14. Cellubril Capsules

15. Tibamycin Capsules

16. Leprostat

As regards the remaining items the company is reported to have discontinued these and has given an Undertaking that in case their production is commenced, they would seek necessary Industrial Approval.

4 M/s Glaxo Laboratories Ltd.

1. Analgesic

2. Entacyl

3. Ergot

4. Compound Ferrous Sulphate

5. Livogen

6. Crystapen V 65 mg.

7. Crystapen V 125 mg.

8. Crystapen V 250 mg.

9. Macrabin 50 mcg.

10. Ancolan

11. Multivito Forte

12. Multimineral

13. Pelonin 250 mg.

14. Remids

15. Vitcolin 100 mg.

16. Ostocalcium B 12 with C

17. Multivite F. M.

18. Prepalin Forte

19. Aminophylline

20. Livogen (Inc Vet).

21. Protaomine Sulphate

22. Estomycin

23. Herogen

24. Vibelan Forte Into Vit. C. Caps.

25. Vitneurin Inj.

26. Gastina Tabs.